Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

Get Ready For The Return Of The Mega-Merger, Leerink Says

Following tax reform, analysts expect imminent biopharma mega-mergers, with Pfizer, Merck and Roche looking to buy, AstraZeneca, Bristol and Vertex looming as take-out candidates, and Amgen as either a buyer or a target.
M & A Business Strategies Commercial

Lundbeck Snaps Up Parkinson's Developer Prexton In Deal Worth €905m

Lundbeck has swooped in to buy Merck KGaA spinout Prexton Therapeutics for €100m upfront, prior to Phase II data readouts for its potential first-in-class Parkinson's drug, foliglurax.

M & A Deals Neurology

Exelixis Eyes Liver Cancer OK To Help Drive Cabometyx Sales

Exelixis is looking to get its kidney cancer drug Cabometyx approved for hepatocellular carcinoma as well, but the therapy's long-term success is reliant on combinations with checkpoint inhibitors

Cancer Drug Review FDA

 Recent Tweets from Scrip


Commercial Explore this Topic

Set Alert for Commercial

Finance Watch: Despite Bad News, IPOs And Public Offerings Keep Flowing

Solid Biosciences was able to launch an IPO earlier this year despite a last minute disclosure about a partial clinical hold, which is now a full clinical hold that's cost investors money. Even so, Arcus Biosciences was able to launch its IPO. Ideaya, JW lead recent VC financings.

Financing Business Strategies StartUps and SMEs

PsiOxus Pursues CAR-T Mirror Image Strategy Into Clinic

Bankrolled by upfront and milestone payments associated with deals it has with Bristol-Myers Squibb, Oxford, UK-based gene therapy company PsiOxus Therapeutics is targeting two INDs in 2018 and two in 2019. Company CEO John Beadle outlined his near term plans for the unpartnered programs to Scrip during the 2018 Biotech Showcase.

StartUps and SMEs Cancer BioPharmaceutical

After Bad Data Comes Layoffs – Will The Next Job Cuts Be At Anthera?

Anthera is exploring strategic alternatives after its lead drug candidate Sollpura failed in Phase III, which means layoffs may be coming soon. Several other biopharma companies have had to turn to job cuts already this year.

Business Strategies Clinical Trials

Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis

Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.

Deals M & A

Diurnal's £11m Placing To Promote First Product Launch And Pipeline

Diurnal's CEO Martin Whitaker says 2018 promises to be transformational for the late-stage endocrinology company.

Financing Business Strategies

Vernalis Seeks Buyers, CEO To Step Down, As US Commercial Strategy Disappoints

Disappointing sales growth of its prescription extended-release cough-and-cold product has led Vernalis to decide to close down its US commercial operations, and to seek a buyer for the whole company.


Business Strategies Infectious Diseases

Going Solo Suits Vifor And Its Hopes For Two Blockbusters

Enjoying its independence from Galenica, Switzerland’s third-largest pharmaceutical company believes that Ferinject and Veltassa will help it achieve sales of over CHF2bn by 2020.

Sales & Earnings Renal

Escalier Raises $19m To Advance Psoriasis Assets

Escalier Biosciences will use recently raised cash, from an investment round led by Forbion Capital Partners, to progress oral and topical psoriasis therapies into the clinic.

Financing Business Strategies

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

The FDA Commissioner called on payers to take steps to build the US biosimilar market and discouraged some early contracting schemes, calling them pay-for-delay tactics "dressed in the guise of rebates" in a notable speech at AHIP.

Biosimilars Pricing Debate FDA

Theratechnologies Sets $118k Yearly Price For HIV Biologic Trogarzo

The company's monoclonal antibody for multidrug resistant HIV-1 patients licensed from TaiMed will launch soon.

Approvals Pricing Strategies

AZ Sees A Future For Forxiga In Type 1 Diabetes

The EMA is looking at a marketing authorization variation for the type 2 diabetes blockbuster SGLT-2 inhibitor for use as an oral adjunct treatment to insulin in adults with type 1. Observers will be interested to see what stance the agency takes on the slightly higher number of diabetic ketoacidosis events seen in trials supporting the submission.

Metabolic Disorders Drug Review

US IP Index Based On 'Flawed' Assumptions, Claim Indian Pharma Firms

Indian drug makers have blasted the US Chamber of Commerce’s Global Innovation Policy Center over its International IP Index, saying its compilation is based on a “flawed” assumption that stronger patents drive greater innovation, and that it ignores individual national concerns.

India Policy & Regulation

Research & Development Explore this Topic

Set Alert for Research & Development

Adaptimmune Hits High With TCR Platform Success With GSK Licensed Product

The T-cell therapy company has been tipped as a potential leader in a potentially disruptive field as new data support wide application in cancer.

Clinical Trials Cancer Research & Development

Pipeline Watch: Phase III Starts With Oxabact, Imeglimin And Favipiravir

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.



Pipeline Watch Approvals

Alexion's Defensive Play Poised To Pay Off

The company's long-acting C5 complement inhibitor ALXN1210 demonstrated non-inferiority to Soliris in a Phase III trial, which should help the company defend against anticipated competition to its blockbuster franchise.

Blood & Coagulation Disorders Rare Diseases

Sosei Looks To Add Value Through Pipeline Progress

Japan-based Sosei is building up its portfolio of in-house assets on top of technology and molecule licensing deals as it looks to create value over the next few years following the acquisition of Heptares, say executives.

Japan Research & Development